Dr. Palacios concluded his presentation discussing the role of an intraoperative steep Trendelenburg break during robot-assisted laparoscopic radical prostatectomies with the following take-home ...

However, the association between low testosterone levels and grade group progression among men with prostate cancer managed on active surveillance remains unclear. This study, presented at the 2025 ...

There were 27 patients with 30 affected renal units identified, of which 13 renal units (43%) were treated with kidney-sparing surgery and UGN-101, and 17 renal units (57%) were treated with ...

The immune checkpoint inhibitor combination regimen has become the initial standard of care for metastatic RCC, given its significant survival benefit over sunitinib. Importantly, deferred nephrectomy ...

Intravesical cretostimogene is administered in combination with n-dodecyl-β-D-maltoside (DDM), an excipient that enhances adenoviral delivery, for 6 weekly doses during the induction phase, followed ...

The 2025 South Central AUA annual meeting included a session on urothelial cancer, featuring a presentation from Dr. Patrick Burnam discussing long-term outcomes of adjuvant UGN-101 in a real-world ...

Neoadjuvant systemic therapy was acceptable to 70% of patients, with 69% of those willing to undergo renal mass biopsy first. While 52% would consider neoadjuvant systemic therapy for ≥16 weeks and 56 ...

Moderated by Dr. Thomas Chi (UAB), the panel featured Dr. Vernon Pais (Dartmouth), Dr. Karen Stern (Mayo Clinic Arizona), Dr.

Detalimogene voraplasmid is a novel, investigational, non-integrating, non-viral genetic medicine-based immunotherapy carrying a plasmid that simultaneously expresses IL-12 and regulators of RIG-I.

In a real-world, multi-center cohort, patients receiving LHRH agonists as compared to LHRH antagonists were found to be at ...

The 2025 South Central AUA annual meeting included a session on bladder cancer, featuring a presentation from Dr. Yair Lotan discussing 1-year outcomes of TAR-200 monotherapy in patients with ...

Post-immune checkpoint inhibitor cytoreductive nephrectomy may be a safe and feasible treatment strategy in appropriately selected patients, with low rates of major intraoperative or post-operative ...